Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Mobile Lung Cancer Screening in an Underserved Population Finds High Incidence of Concurrent Disease States
ASCO 2021 – Lung Cancer
A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers.
Read More ›
Racial Disparities with Use of Chemotherapy plus Radiotherapy Among Patients with Stage III NSCLC
ASCO 2021 – Lung Cancer
Analysis of the National Cancer Database indicates that a lower proportion of black patients with locally advanced, stage III, non–small-cell lung cancer (NSCLC) receive concurrent chemotherapy plus radiotherapy compared with white patients.
Read More ›
IMpower010: Atezolizumab versus Best Supportive Care Post-Adjuvant Chemotherapy in Resected NSCLC
ASCO 2021 – Lung Cancer
Atezolizumab in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC) extends disease-free survival compared with best supportive care after receiving adjuvant chemotherapy.
Read More ›
Patient-Reported Outcomes from the Phase 2 CodeBreaK 100 Trial Evaluating Sotorasib in KRAS p.G12C–Mutated NSCLC
ASCO 2021 – Lung Cancer
Patients with pretreated
KRAS
p.G12C–mutated non–small-cell lung cancer (NSCLC) treated with sotorasib improved or maintained global health status/quality of life, physical functioning, and the severity of key lung cancer–related symptoms.
Read More ›
Racial Disparities in Follow-Up Care of Early-Stage Lung Cancer Survivors
ASCO 2021 – Lung Cancer
Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation.
Read More ›
Health-Related Quality-of-Life Results of the KEYNOTE-598 Trial in Patients with Metastatic NSCLC with PD-L1 Tumor Proportion Score ≥50%
ASCO 2021 – Lung Cancer
Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%.
Read More ›
Clinical Utility of Cell-Free Genomic Profiling in Advanced Lung Adenocarcinoma
ASCO 2021 – Lung Cancer
Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma.
Read More ›
CodeBreaK 100: Efficacy Results from a Phase 2 Trial in Pretreated KRAS G12C–Mutated NSCLC
ASCO 2021 – Lung Cancer
Sotorasib, an oral
KRAS
inhibitor, was effective across specified subgroups of patients with
KRAS
G12C–mutated non–small-cell lung cancer (NSCLC).
Read More ›
Cost Evaluation of Adjunctive Osimertinib Use in Resected EGFR-Positive NSCLC
ASCO 2021 – Lung Cancer
The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected
EGFR
-positive non–small-cell lung cancer (NSCLC).
Read More ›
Active Multimodal Intervention Reduced Racial Disparities in Delivery of Timely Lung Cancer Surgery
ASCO 2021 – Lung Cancer
The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer.
Read More ›
Page 47 of 147
44
45
46
47
48
49
50
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us